Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 64 of 95, showing 5 Applications out of 471 total, starting on record 316, ending on 320

# Protocol No Study Title Investigator(s) & Site(s)

316.

ECCT/17/07/01   ABCD
    Antibiotics for Children with Severe Diarrhea Trial   
Principal Investigator(s)
1. Judd Walson
Site(s) in Kenya
1. Rongo Sub-County Hospital (Migori county)
2. Ndhiwa Sub-County Hospital (Homa Bay county)
3. Rachuonyo Sub-County Hospital (Homa Bay county)
4. Isebania Sub-County Hospital (Migori county)
5. Awendo Sub-County Hospital (Migori county)
6. Mbita Sub-County Hospital (Homa Bay county)
 
View

317.

ECCT/17/06/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
2. KAVI Institute of Clinical Research (Nairobi City county)
 
View

318.

ECCT/17/06/01   MF/PM Phase III
    An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa       
Principal Investigator(s)
1. Jane Mbui
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba sub-county hospital (West Pokot county)
 
View

319.

ECCT/17/05/04   Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost
    A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WALTER REED KERICHO
 
View

320.

ECCT/17/05/03   TDF IVR-002 Study
    Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Health Research & Development (Thika Partners Clinical Trial Site)
 
View